From: Frontini, Roberto [mailto:Roberto.Frontini@medizin.uni-leipzig.de]

Sent: 22 March 2013 16:07

To: 'François Houyez'; 'Jurate Svarcaite'; Tony West; Richard Price

Cc: 'Haerry'

Subject: RE: shortages in France

Dear Francois,

Caelix was the biggest problem in the field of Oncology. It looks leike the shortage will end in April/May.

We have problems with 5-FU, a standard oncology drug. Big problems with Fosfomycin (an antibiotic agent). Just 2 examples
Best regards

web: http://www.medizin.uni-leipzig.de

This e-mail may contain confidential and/or privileged information. If you are not the intended recipient (or have received this e-mail in error) please notify the sender immediately and destroy this e-mail. Any unauthorized copying, disclosure or distribution of the material in this e-mail is strictly forbidden.

From: François Houyez [mailto:francois.houyez@eurordis.org]

**Sent:** Friday, March 22, 2013 3:07 PM

To: Jurate Svarcaite; <a href="mailto:Tony.West@gstt.nhs.uk">Tony.West@gstt.nhs.uk</a>; <a href="mailto:richard.price@eahp.eu">richard.price@eahp.eu</a>; Frontini, Roberto

**Cc:** Haerry

**Subject:** shortages in France

Dear Jurate, Toni, Roberto and Richard,

The documents you've sent (your respective statements on supply shortages in 2012) are highly appreciated and have initiated a high interest at Eurordis and in other organisations in France.

I was wondering if any of you had examples of specific shortages that are a concern for public health currently. I don't even know if the Caelyx shortage is over or not, and some are talking about other cancer drugs but nobody has really clear information.

Would you know?

Thank you in advance, Best regards, François

François Houÿez Treatment Information and Access Director / Health Policy Advisor EURORDIS

EURORDIS Paris' Office- Plateforme Maladies Rares, 96 rue Didot, 75014 Paris - France +33 1 56 53 52 18